脫氫表雄酮 DHEA

INT-dehydroepiandrosterone-001 3 個適應症被研究

D 2 U 1

適應症與證據等級

更年期 Menopause

D 🔴 D 反證據主流反證據 🚨 高市場風險

抗老化 Aging

D 🔴 D 反證據主流反證據 🚨 高市場風險

男性不孕 Male Infertility

U ⚫ U 未驗證證據不足 🚨 高市場風險

法規與權威立場 (L4)

L4a · US FDA

立場：cautious

Intrarosa (prasterone) is the first FDA-approved product containing the active ingredient prasterone, also known as dehydroepiandrosterone (DHEA).

L4b · EU EFSA

立場：against

L4c · UK NHS

立場：against

DHEA is classed as a prescription-only medicine in the UK and is also a Class C controlled drug.

L4d · TW TFDA / 衛福部

立場：against

DHEA（脫氫表雄酮）在台灣屬於藥品列管，不論劑量高低均以藥品管理，須由醫師開立處方；不得作為食品或膳食補充劑販售。

L4e · WHO

立場：cautious

DHEA is included in the pharmacological class S1 'Anabolic Agents' as an Anabolic Androgenic Steroid, prohibited at all times (in and out of competition) under the World Anti-Doping Code.

市場與行銷 (L10)

L10a · TW Market Channels

脫氫表雄酮（DHEA）不分劑量都視為藥品

L10b · TW Legal Identity (TFDA)

脫氫表雄酮（DHEA）不分劑量都視為藥品

L10c · TW Community (PTT/Dcard/Mobile01)

DHEA無法讓卵巢變好，只能讓它盡量不要再惡化